CCO Independent Conference Coverage

2003 Conference on Retroviruses and Opportunistic Infections*

February 10-14, 2003 | Boston, MA

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

First-Line Antiretroviral Therapy

Track 1 of 6

Capsule Summaries

Expert Analysis

Program Director: John P. Phair, MD

Faculty:
		Daniel R. Kuritzkes, MD Kimberly Y. Smith, MD, MPH Kathleen E. Squires, MD

Antiretroviral Resistance, Treatment Interruptions, & Salvage Therapy

Track 2 of 6

Capsule Summaries

Expert Analysis

Program Director: John P. Phair, MD

Faculty:
		Joel E. Gallant, MD, MPH William A. O'Brien, MD, MS Andrew R. Zolopa, MD

Investigational Antiretrovirals

Track 3 of 6

Capsule Summaries

Expert Analysis

Program Director: John P. Phair, MD

Faculty:
		Joseph J. Eron, Jr., MD W. David Hardy, MD William G. Powderly, MD

Pharmacology and Drug-drug Interactions

Track 4 of 6

Capsule Summaries

Expert Analysis

Program Director: John P. Phair, MD

Faculty:
		Edward P. Acosta, PharmD Stephen L. Becker, MD Courtney V. Fletcher, PharmD

Lipodystrophy and Adverse Effects of Therapy

Track 5 of 6

Capsule Summaries

Expert Analysis

Program Director: John P. Phair, MD

Faculty:
		Judith S. Currier, MD, MSc Donald P. Kotler, MD William G. Powderly, MD

Opportunistic Infections and Coinfections

Track 6 of 6

Capsule Summaries

Expert Analysis

Program Director: John P. Phair, MD

Faculty:
		Richard E. Chaisson, MD W. David Hardy, MD Bruce Polsky, MD

CCO Daily News (Not required for CME credit)

February 14, 2003

February 13, 2003

February 11, 2003

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.